Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(}function setPanelState(o){dom.root.classList[o?"add":"remove"](,dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

An independent review into new national standards for prescribing opioids says the process used to craft the measures was scientifically rigorous.

The Canadian Press

The development of new national standards for prescribing opioids was "scientifically rigorous," despite a flawed process for identifying financial ties between an individual who helped craft the measures and the pharmaceutical industry, a report says.

Former federal health minister Jane Philpott ordered an independent review of the guidelines in May to ensure that they were not "tainted" by industry influence. Dr. Philpott's intervention followed a story in The Globe and Mail revealing that officials at McMaster University who developed the guidelines did not honour a pledge to exclude medical experts who receive income from drug companies from voting on the standards.

Sol Stern, a family doctor in Oakville, Ont., and a member of the voting panel, has been a paid speaker and advisory board member for drug companies – which did not come to light until May 8, the day the guidelines were published.

Story continues below advertisement

Related: Opioid panel chair admits conflict-of-interest lapse

Read more: A Killer High: How Canada got addicted to fentanyl

The Canadian Institutes of Health Research, the federal agency asked to conduct the review, issued a report on Thursday, saying: "There is no evidence a COI [conflict of interest] did or could have had any real influence on the final recommendation."

Nav Persaud, a family doctor at Toronto's St. Michael's Hospital who helped craft the new standards, questioned how anybody could know for sure whether a conflict of interest did or did not have an effect on a recommendation.

The controversy around the guidelines highlights the need in Canada for more transparency on conflicts of interest in the medical community, academic and medical experts say.

Pharmaceutical companies in many countries are required to make public their payments to individual doctors, leaving Canada a laggard internationally.

"The fact that there is even the perception of a conflict of interest undermines trust and underscores the importance of having public disclosure and consistent standards when it comes to guidelines," said Andrew Boozary, a resident physician at St. Michael's Hospital who is leading a campaign called Open Pharma, which says patients in Canada should be able to check an online database to see whether their doctors have received funding from the drug industry.

Story continues below advertisement

"This kind of thing could well happen again, and it would be easy to avoid if the federal government was willing to move on the issue," added Joel Lexchin, a professor emeritus at York University's faculty of health and a founder of Open Pharma.

A spokesman for Health Minister Ginette Petitpas Taylor said the minister's office plans to look into Open Pharma's recommendations. "We remain open to new approaches to increase transparency for Canadians," the spokesman said.

The guidelines developed at McMaster are aimed at reversing practices established two decades ago, when pharmaceutical companies promoted the benefits of opioids and doctors began prescribing them to relieve moderate to severe pain. A continuing Globe investigation has traced the roots of Canada's opioid epidemic to the introduction in 1996 of OxyContin, a prescription painkiller made by Purdue Pharma.

The guidelines had not been updated since 2010, leaving them out of step with evidence showing that the risks associated with prescription opioids are substantial and the benefits uncertain. Canada ranks as the world's second-biggest consumer of prescription opioids, after the United States.

In its application to Health Canada for funding to update the guidelines, McMaster says, "The key to developing conflict-free recommendations" is to require all voting panel members to "have no financial or intellectual conflicts."

The research institute's review blames an "administrative oversight" for the fact that one doctor's conflict of interest did not come to light earlier. Had the doctor's industry ties been identified at the beginning of the process, the review says, the committee overseeing the guidelines would have excluded him from the voting panel. The research institute says it found the process used to develop the guidelines "scientifically rigorous despite the flaw in promptly identifying the [conflict of interest] in a single voting member."

Story continues below advertisement

Jason Busse, an associate professor at McMaster's department of anesthesia and co-lead of the group that drafted the guidelines, said in an e-mail that he is pleased with the review, reiterating its finding that one voting panel member's conflict of interest "did not impact the guideline's recommendations."

The College of Physicians and Surgeons of Ontario (CPSO,) the self-regulatory body for doctors in Canada's most populous province, is preparing to update its overall drug-prescribing policy to reflect the McMaster group's opioid guidelines.

The CPSO's council is scheduled to vote Friday on draft changes that direct physicians to rely on the new Canadian opioid-prescribing guidelines and similar ones produced by the U.S. Centers for Disease Control and Prevention. Both "strongly recommend" against prescribing doses above the equivalent of 90 milligrams of morphine per day for patients with chronic, non-cancer pain.

With a report from Kelly Grant

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to If you want to write a letter to the editor, please forward to

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies